Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
CEO | Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. |
IPO Date | Dec. 16, 2021 |
Location | United States |
Headquarters | 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064 |
Employees | 14 |
Sector | Healthcare |
Industry | Biotechnology |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
NA
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email